SCHOTT Pharma, a pharmaceutical drug containment solutions and delivery systems provider, will build its first U.S. facility in Wilson, NC to manufacture prefillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications. The site will also have the capability to produce glass prefillable syringes for GLP-1 therapies, such as those treat diabetes or obesity. The project will add 401 jobs to the region and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.
 
The new site will expand the U.S. supply chain for in-demand syringes for injectable medicines, vaccines, and other fields of applications, allowing SCHOTT Pharma to triple its contribution of glass and polymer syringes to the U.S. market by 2030. Bringing production to the U.S. will reduce lead times and transportation costs, as well as protect against future shortages of critical drugs.
 
“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the U.S.,” said Andreas Reisse, CEO of SCHOTT Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”
 
“Wilson County stood out in a nationwide search for a number of reasons, particularly for its favorable pool of local talent and its proximity to the Research Triangle area, which hosts numerous universities, healthcare companies, and biopharma resources,” said Christopher Cassidy, President of SCHOTT North America. “Expanding operations in the U.S. addresses rapidly growing demand for our high-value solutions.”